Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

Afshar M, Patel HRH, Jain A, Kumar A, Patel P, James ND, Porfiri E.

Expert Rev Anticancer Ther. 2019 Jun;19(6):529-532. doi: 10.1080/14737140.2019.1609355. Epub 2019 May 2.

PMID:
30995130
2.

Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess.

Chortis V, Johal NJ, Bancos I, Evans M, Skordilis K, Guest P, Cullen MH, Porfiri E, Arlt W.

Eur J Endocrinol. 2018 Mar;178(3):K21-K27. doi: 10.1530/EJE-17-0542. Epub 2018 Jan 12.

3.

Spontaneous CD4+ and CD8+ T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients.

Pearce H, Hutton P, Chaudhri S, Porfiri E, Patel P, Viney R, Moss P.

Eur J Immunol. 2017 Jul;47(7):1232-1242. doi: 10.1002/eji.201646898. Epub 2017 Jun 26.

4.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MKB, Sydes MR; STAMPEDE Investigators.

J Clin Oncol. 2017 May 10;35(14):1530-1541. doi: 10.1200/JCO.2016.69.0677. Epub 2017 Mar 13.

5.

A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E.

Anticancer Res. 2017 Jan;37(1):253-259.

PMID:
28011500
6.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S.

J Clin Oncol. 2017 Jan 10;35(2):194-200. Epub 2016 Nov 28. Erratum in: J Clin Oncol. 2017 Mar;35(7):812.

7.

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.

Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530.

8.

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.

BJU Int. 2017 Apr;119(4):522-529. doi: 10.1111/bju.13549. Epub 2016 Jul 10.

9.

An Unusual Cause of Subacute Headache in a Patient Undergoing Chemotherapy for Advanced Testicular Nonseminomatous Germ Cell Tumour.

Clarke HM, Rao AR, Porfiri E.

Case Rep Oncol Med. 2016;2016:4317108. doi: 10.1155/2016/4317108. Epub 2016 Apr 21.

10.

MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome.

Wragg JW, Finnity JP, Anderson JA, Ferguson HJ, Porfiri E, Bhatt RI, Murray PG, Heath VL, Bicknell R.

Cancer Res. 2016 Apr 15;76(8):2314-26. doi: 10.1158/0008-5472.CAN-15-1364. Epub 2016 Feb 26.

11.

The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.

Bardoli AD, Afshar M, Viney R, Foster M, Porfiri E, Zarkar A, Stevenson R, James ND, Bryan RT, Patel P.

Future Oncol. 2016 Mar;12(5):595-600. doi: 10.2217/fon.15.337. Epub 2016 Feb 1. Review. No abstract available.

PMID:
26880382
12.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ.

JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570.

13.

Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.

Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, Brown J, Buchan S.

Ann Oncol. 2016 Jan;27(1):159-65. doi: 10.1093/annonc/mdv504. Epub 2015 Oct 21.

14.

Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.

Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James ND, Porfiri E.

Anticancer Res. 2015 Feb;35(2):1057-63.

PMID:
25667494
15.

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.

Afshar M, Pascoe J, Whitmarsh S, James N, Porfiri E.

Drug Des Devel Ther. 2014 Dec 17;9:13-9. doi: 10.2147/DDDT.S73686. eCollection 2015.

16.

The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.

Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, Montgomery B, Bryan RT.

Ann R Coll Surg Engl. 2014 Sep;96(6):415-9. doi: 10.1308/003588414X13946184901001. Review.

17.

The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.

Caldarella C, Muoio B, Isgrò MA, Porfiri E, Treglia G, Giovanella L.

Radiol Oncol. 2014 Jul 10;48(3):219-27. doi: 10.2478/raon-2013-0067. eCollection 2014 Sep. Review.

18.

Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.

Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT.

Future Oncol. 2014 Jun;10(8):1443-56. doi: 10.2217/fon.14.79. Review.

PMID:
25052754
19.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.

Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.

20.

Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.

Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar M, Porfiri E.

Clin Genitourin Cancer. 2014 Aug;12(4):251-5. doi: 10.1016/j.clgc.2013.12.001. Epub 2013 Dec 27.

PMID:
24560086
21.

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W.

J Clin Endocrinol Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16.

22.

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME.

Eur J Cancer. 2012 Mar;48(4):527-37. doi: 10.1016/j.ejca.2011.12.022. Epub 2012 Jan 28.

PMID:
22285180
23.

Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.

Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM.

J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84. doi: 10.1210/jc.2011-1565. Epub 2011 Sep 14.

24.

Sunitinib-induced acute psychosis: case report.

Kunene V, Porfiri E.

Clin Genitourin Cancer. 2011 Sep;9(1):70-2. doi: 10.1016/j.clgc.2011.03.001. Epub 2011 Apr 28. No abstract available.

PMID:
21729680
25.

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.

Oncol Rep. 2010 Aug;24(2):507-10.

PMID:
20596640
26.

Delays incurred during acute myocardial infarction: a comparative study of rural and urban populations in Greece.

Vavouranakis I, Fanioudaki A, Lamprogiannakis E, Baltzakis I, Sidiropoulou K, Porfiri E, Ganotakis ES.

Rural Remote Health. 2010 Apr-Jun;10(2):1271. Epub 2010 May 28.

27.

Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.

James N, Pascoe J, Zachariah A, Ray D, Oldroyd A, Parry H, Benghiat H, Karina M, Collins S, Porfiri E.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):610-6. doi: 10.1016/j.clon.2009.06.007. Epub 2009 Aug 19.

PMID:
19695849
28.
29.

Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E.

Clin Genitourin Cancer. 2009 Aug;7(2):E39-41. doi: 10.3816/CGC.2009.n.021.

PMID:
19692322
30.

UK guidelines for the systemic treatment of renal cell carcinoma.

Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T.

Br J Hosp Med (Lond). 2009 May;70(5):284-6. Review.

PMID:
19451873
31.

Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.

Jafri M, Douis H, Porfiri E.

Clin Oncol (R Coll Radiol). 2008 Oct;20(8):657-8. doi: 10.1016/j.clon.2008.06.002. Epub 2008 Jul 21. No abstract available.

PMID:
18644704
32.

Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC.

Bianchi F, Galizia E, Bracci R, Belvederesi L, Catalani R, Loretelli C, Giorgetti G, Ferretti C, Bearzi I, Porfiri E, Cellerino R.

Clin Genet. 2007 Feb;71(2):158-64.

PMID:
17250665
33.

A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy.

Bianchi F, Galizia E, Porfiri E, Belvederesi L, Catalani R, Loretelli C, Bracci R, Bearzi I, Turchi C, Viel A, Cellerino R.

Fam Cancer. 2007;6(1):97-102.

PMID:
17165155
34.

Beta-catenin gene analysis in oral squamous cell carcinoma.

Lo Muzio L, Goteri G, Capretti R, Rubini C, Vinella A, Fumarulo R, Bianchi F, Mastrangelo F, Porfiri E, Mariggiò MA.

Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3 Suppl):33-8.

PMID:
16848985
35.

MSH2 splice site mutation and endometrial cancer.

Bianchi F, Rosati S, Belvederesi L, Loretelli C, Catalani R, Mandolesi A, Bracci R, Bearzi I, Porfiri E, Cellerino R.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1419-23.

PMID:
16803540
36.

Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features.

Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Galizia E, Bracci R, Rosati S, Bearzi I, Viel A, Cellerino R, Porfiri E.

Eur J Hum Genet. 2006 Jul;14(7):853-9. Epub 2006 May 17.

37.

Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.

Piga A, Gesuita R, Catalano V, Nortilli R, Cetto G, Cardillo F, Giorgi F, Riva N, Porfiri E, Montironi R, Carle F, Cellerino R.

Oncology. 2005;69(2):135-44. Epub 2005 Aug 24.

PMID:
16127284
38.

'Secrets and lies'--the difficulties of communicating within families with inherited cancer syndromes.

Bianchi F, Rosati S, Belvederesi L, Loretelli C, Ferretti B, Bearzi I, Piga A, Cellerino R, Porfiri E.

Clin Genet. 2004 Nov;66(5):476-7. No abstract available.

PMID:
15479195
39.

Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.

Berardi R, Porfiri E, Scartozzi M, Lippe P, Silva RR, Nacciarriti D, Menichetti ET, Tummarello D, Carle F, Piga A, Cellerino R.

Oncology. 2003;65(3):198-203.

PMID:
14657592
40.

Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients.

Scartozzi M, De Nictolis M, Galizia E, Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R, Porfiri E.

Eur J Cancer. 2003 May;39(8):1144-9.

PMID:
12736115
41.

Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.

Scartozzi M, Bianchi F, Rosati S, Galizia E, Antolini A, Loretelli C, Piga A, Bearzi I, Cellerino R, Porfiri E.

J Clin Oncol. 2002 Mar 1;20(5):1203-8.

PMID:
11870161
42.

Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.

Lippe P, Tummarello D, Monterubbianesi MC, Silva RR, Giuliodori L, Mari D, Santo A, Pasini F, Cetto GL, Rossi D, Porfiri E, Cascinu S, Cellerino R.

Ann Oncol. 1999 Feb;10(2):217-21.

PMID:
10093692
43.

Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin.

Porfiri E, Rubinfeld B, Albert I, Hovanes K, Waterman M, Polakis P.

Oncogene. 1997 Dec 4;15(23):2833-9.

44.
45.

Stabilization of beta-catenin by genetic defects in melanoma cell lines.

Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P.

Science. 1997 Mar 21;275(5307):1790-2.

46.

Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly.

Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P.

Science. 1996 May 17;272(5264):1023-6.

PMID:
8638126
47.
48.

Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway.

van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ.

Nature. 1995 Aug 31;376(6543):781-4.

PMID:
7651538
49.

The Grb2 binding domain of mSos1 is not required for downstream signal transduction.

Wang W, Fisher EM, Jia Q, Dunn JM, Porfiri E, Downward J, Egan SE.

Nat Genet. 1995 Jul;10(3):294-300.

PMID:
7670467
50.

DCC (deleted in colorectal cancer) inactivation in hematological malignancies.

Porfiri E.

Leuk Lymphoma. 1995 Jun;18(1-2):69-72. Review.

PMID:
8580831

Supplemental Content

Loading ...
Support Center